|Videos|November 3, 2021

Oral testosterone undecanoate shows promising results for first use in the real world

“We were surprised to see that the majority of subjects in these simulations had testosterone levels within eugonadal range for all 3 dose's studies,” says Jay Newmark, MD, MBA.

In this video, Jay Newmark, MD, MBA, discusses the background, findings, and takeaways of the study, “Real-World Experience with First FDA-Approved Oral Testosterone Undecanoate Formulation,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Newmark is a chief medical officer at Clarus Therapeutics, Northbrook, Illinois.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Related Content

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
Virtual Event

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

View more
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

View more